百赛诺对慢性乙型肝炎患者细胞免疫应答的影响

南方医科大学学报 ›› 2005, Vol. 25 ›› Issue (06): 706-708.

百赛诺对慢性乙型肝炎患者细胞免疫应答的影响

施斌斌¹, 彭劼¹, 温帆渊², 侯金林¹

1. 南方医科大学南方医院感染内科, 广东, 广州, 510515;
2. 惠州市中心医院, 广东, 惠州, 515600

出版日期:2005-06-20 发布日期:2005-06-20
基金资助:
收稿日期:2004-11-9。
作者简介:施斌斌(1974- ),男,主治医师,在读硕士研究生,电话:020-61641944,E-mail;gootlight2001@sina.com

Effect of bicyclol tablets on cellular immune responses in patients with chronic hepatitis B

SHI Bin-bin¹, PENG Jie¹, WEN Fan-yuan², HOU Jin-lin¹

1. 南方医科大学南方医院感染内科, 广东, 广州, 510515;
2. 惠州市中心医院, 广东, 惠州, 515600

Online:2005-06-20 Published:2005-06-20

摘要/Abstract

摘要： 目的研究百赛诺治疗慢性乙型肝炎(CHB)对患者外周血单个核细胞(PBMC)培养上清IL-4、IL-10和IFN-γ水平的影响。方法选择30例CHB患者给予百赛诺治疗,分别在治疗前、治疗后1个月和3个月抽取全血,同时选择7例健康人群作为对照组。结果 CHB组PBMC培养上清分泌IL-4水平显著高于对照组[(17.18±7.43)pg/mlvs(8.24±4.16)pg/ml,P<0.05],而IFN-γ水平则显著低于对照组[(36.25±19.92)pg/mlvs(121.68±44.40)pg/ml,P<0.01)];百赛诺治疗后,在第3个月IFN-γ水平较治疗前显著升高[(53.19±7.28)pg/mlvs(36.25±19.92)pg/ml,P<0.05],IL-4水平则较治疗前显著降低[(9.74±7.75)pg/mlvs(17.18±7.43)pg/ml,P<0.01];HBeAg阳性组百赛诺治疗后IL-4水平较治疗前下降,IFNγ水平较治疗前上升,均有统计学意义[(8.74±6.12)pg/mlvs(20.51±9.16)pg/ml,(50.71±30.76)pg/mlvs(26.03±10.48)pg/ml,P<0.05];而HBeAg阴性组各细胞因子水平治疗前后无明显差异(P>0.05)。结论百赛诺治疗CHB可提高患者Th1型细胞因子、降低Th2型细胞因子水平,在CHB治疗中有一定调节免疫功能的临床价值。

Abstract: Objective To study the effect of bicyclol tablets on the levels of interleukin (IL)-4, IL-10 and interferon (IFN)-γ in culture supernatants of peripheral blood mononuclear cells (PBMCs) from patients with chronic hepatitis B (CHB). Methods Whole blood samples were obtained from 30 patients with CHB before and at 1 and 3 months during bicyclol tablet therapy and also from 7 healthy donors for isolation of the PBMCs. The product of IL-4, IL-10 and IFN-γ in the culture supernatant of PBMCs were determined by enzyme-linked immunosorbent assay (ELISA) after 72 h of cultivation. Results At 3 months during the therapy, the level of IFN-γ was increased significantly in the patients from 36.25±19.92 pg/ml to 53.19±7.28 pg/ml (P<0.05) and the level of IL-4 significantly decreased from 17.18±7.43 pg/ml to 9.74±7.75 pg/ml (P<0.01). The changes in the levels of IL-4 and IFN-γ at 3 months during therapy were more obvious in patients with HBeAg positivity than in HBeAg-negative patients (8.74±6.12 pg/ml vs 20.51±9.16 pg/ml, 50.71±30.76 pg/ml vs 26.03±10.48 pg/ml, respectively, P<0.05). Conclusion Bicyclol tablets not only promote Th1 type cytokine-mediated immune responses but also down-regulates Th2 type cytokine-mediated immune responses.

中图分类号:

施斌斌¹, 彭劼¹, 温帆渊², 侯金林¹. 百赛诺对慢性乙型肝炎患者细胞免疫应答的影响[J]. 南方医科大学学报, 2005, 25(06): 706-708.

SHI Bin-bin¹, PENG Jie¹, WEN Fan-yuan², HOU Jin-lin¹. Effect of bicyclol tablets on cellular immune responses in patients with chronic hepatitis B[J]. Journal of Southern Medical University, 2005, 25(06): 706-708.

参考文献

[1] 刘耕陶.双环醇的抗病毒与肝细胞保护作用及其作用机制[J].中国新药杂志,2001,10(5):325-7.Liu GT. The anti-virus and hepatoprotective effect of bicyclol and its mechanism of action[J]. Chin J New Drugs, 2001, 10(5):325-7.
[2] 中华医学会传染病与寄生虫病学分会、肝病学分会联合修订.病毒性肝炎防治方案[J].中华肝脏病杂志(Chin J Hepato1),2000,8(6):324-9.
[3] Milich DR. Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection[J]. J Virol Hepatol, 1997, 4(2):248-59.
[4] O’Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets [J]. Immunity, 1998, 8(3):275-83.
[5] Bertoletti A, Maini MK. Protection or damage:a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C virus[J]. Curr Opin Immunol, 2000, 12(4):403-8.
[6] Nishimura T, Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice[J]. J Immunol, 1999, 162(11):6503-9.
[7] Rico MA, Quiraga JA, Subira D. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha[J]. Hepatology, 2001, 33(1):295-300.
[8] Rossol S, Marinos G, Carussl P, et al. Interleuktin-12 induction of Thl cytokines is important for virus clearance in chronic hepatitis B[J]. J Clin Invest, 1997, 99(12):3025-33.
[9] Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B[J]. J Clin Invest,1998, 102(5):968-75.
[10] Bozkaya H, Bozdayi M, Turkyilmaz R, et al. Circulating IL-2, IL-10and TNF-alpha in chronic hepatitis B:their relations to HBeAg status and the activity of liver disease [J]. Hepatogastroenterology,2000, 47(36):1675-9.
[11] 姜荣龙,冯筱榕,郭亚兵,等.慢性乙型肝炎患者HBcAg特异性Th细胞克隆的建立及初步分析[J].第一军医大学学报,2001,21(9):676-8.Jiang RL, Feng XR, Guo YB, et al. Establishment and analysis of HBcAg-specific T helped clones in patients with chronic hepatitis B[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2001, 21(9):676-8.
[12] Pancholi P, Lee DH, Liu Q, et al. DNA prime/canarypox boost-based mmunotherapy of chronic hepatitis B virus infection in a chimpanzee [J]. Hepatology, 2001, 33(2):448-54.